Clinical research on temozolomide chemotherapy for adult diffuse low-grade gliomas

VernacularTitle:成人弥漫性低级别胶质瘤替莫唑胺化疗的临床研究
Author: Baoshi CHEN ; Wei ZHANG ; Zhong ZHANG ; Tao JIANG
Publication Type:Journal Article
Keywords: adult diffuse low-grade gliomas; progression-free survival; temozolomide; chemotherapy
From: Chinese Journal of Clinical Oncology 2016;43(17):753-756
CountryChina
Language:Chinese
Abstract: Objective:To compare the therapy effects of chemotherapy and non-chemotherapy groups and to determine the value of chemotherapy for adult diffuse low-grade gliomas. Methods:We reviewed and analyzed 64 patients with adult diffuse low-grade glio-mas admitted to the Beijing Tiantan Hospital from May 2005 to April 2008. Among the patients, 18 received 4 to 12 cycles of temozolo-mide chemotherapy after operation and radiotherapy, whereas the other 46 cases only received radiotherapy. The progression-free survival of the two groups was compared. Results:The median progression-free survival of the chemotherapy and the control groups were 67.8 and 51.3 months, respectively. The results of the comparison implied a significant difference (χ2=8.741, P=0.003). Conclu-sion:Chemotherapy can improve the progression-free survival of the patients with adult diffuse low-grade gliomas, and thus, can be recommended as its effective therapy.